BFBIO 1QFY27 profit rises 16%

October 28, 2026 (MLN): BF Biosciences Limited (PSX: BFBIO) posted a 16% increase in its net profit for the first quarter ended September 30, 2026 (1QFY27 / 3MFY27), reaching Rs184.88m compared to Rs159.52m in the corresponding period of the previous fiscal year.

Reflecting this bottom-line expansion, basic and diluted earnings per share (EPS) for the three-month period grew 15% to Rs2.09, up from Rs1.81 in 3MFY26.

The primary catalyst driving earnings was a 14% expansion in top-line revenue alongside improved gross margins.

Net revenue for the quarter rose to Rs2.78bn compared to Rs2.43bn in 3MFY26. Cost of goods sold rose by a contained 8% to Rs1.50bn from Rs1.39bn, enabling gross profit to surge 24% to Rs1.28bn from Rs1.04bn.

This resulted in an expansion of the company's gross profit margin to 46.14% compared to 42.69% in the comparative period.

On the operational side, overheads expanded as selling and distribution expenses rose 22% to Rs865.69m (up from Rs709.17m), administrative expenses surged 86% to Rs74.31m (up from Rs39.85m), and other expenses increased 11% to Rs29.97m.

Despite a 73% decline in other income to Rs9.51m (down from Rs34.85m), profit from operations expanded 9% to Rs324.09m against Rs297.05m recorded in 3MFY26.

Below the operating line, finance costs climbed 14% to Rs30.09m compared to Rs26.39m in the prior-year period.

Profit before tax increased 10% to Rs294m from Rs267.89m (with nil minimum tax differential and final tax, compared to Rs2.77m previously).

Following an income tax expense of Rs109.12m (up 1% from Rs108.37m), BF Biosciences Limited closed the first quarter with a net profit of Rs184.88m.

Copyright Mettis Link News